Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
Trial details
- Registry ID
- NCT07211958
- Drugs studied
- Intensive Chemotherapy Regimen, Revumenib
TrialRedline tracks 4 clinical trials sponsored by Syndax Pharmaceuticals: 1 Phase 3, 3 Phase 2.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 MutationNCT07211958 | Intensive Chemotherapy Regimen, Revumenib | Recruiting | 2029-06Estimated |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)NCT04710576 | Axatilimab | Recruiting | 2023-04-07Actual |
| MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)NCT06132256 | Axatilimab | Completed | 2026-08-27Actual |
| A Phase 2 Exploratory Study of Erlotinib and SNDX-275 in Participants With Non-small Cell Lung Carcinoma Who Are Progressing on ErlotinibNCT00750698 | Entinostat, Erlotinib | Terminated | 2010-05Actual |
Names as written in the registry records.
NCT06132256 · Syndax Pharmaceuticals
Before: Estimated. After: Actual.
Before: Sep 2026. After: 27 Aug 2026.
Before: Active not recruiting. After: Completed.
NCT04710576 · Syndax Pharmaceuticals
Before: Actual. After: Estimated.
Before: 241 participants (actual). After: 296 participants (planned).
Before: Active not recruiting. After: Recruiting.
NCT06132256 · Syndax Pharmaceuticals
Before: Estimated. After: Actual.
Before: 135 participants (planned). After: 145 participants (actual).
Before: Recruiting. After: Active not recruiting.
NCT07211958 · Syndax Pharmaceuticals
Before: Not yet recruiting. After: Recruiting.